Literature DB >> 9365549

Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin.

X S Lin1, S R Denmeade, L Cisek, J T Isaacs.   

Abstract

BACKGROUND: More than 95% of metastatic androgen independent prostatic cancer cells per day are in a proliferatively quiescent G0 state [Berges et al.: Clin Cancer Res 1:473-480, 1995] limiting their responsiveness to anti-proliferative chemotherapeutic agents. Novel therapeutics capable of activating the programmed (apoptotic) death pathway in these cells without requiring entrance into the proliferative cell cycle are urgently needed. Thapsigargin (TG) treatment of rapidly growing androgen independent prostatic cancer cells arrests such cells in G0 and induces their programmed death. This raises not only the issue of the mechanism for such growth arrest, but also whether this programmed death is simply a response of rapidly growing cells to growth arrest making cytotoxicity still dependent upon the initial rate of cell proliferation.
METHODS: To resolve the mechanism of TG induced growth arrest, rat AT3.1 prostatic cancer cells were analyzed for RNA and protein expression of the growth arrest gene, gadd153, intracellular free Ca2+ levels (Cai), and cell cycle distribution on exposure to TG alone and in combination with Ca2+ chelation induced by BAPTA-AM or BAPTA-AM/EGTA. To resolve whether growth arrest is required for TG cytotoxicity, primary cultures of proliferatively quiescent, human prostatic cancer cells were exposed to TG.
RESULTS: Co-treatment of androgen independent AT-3 rat prostatic cancer cells with the Cai chelator BAPTA plus TG prevented growth arrest, as monitored by DNA flow cytometry, and failure to induce mRNA and protein for gadd153, demonstrating that growth arrest is due to Cai elevation, not depletion of intracellular Ca2+ pools. In addition, proliferatively quiescent G0 primary cultures of human prostatic cancer cells were resistant to anti-proliferative agents, but could be induced to undergo programmed death by TG as documented by morphological criteria and 14C-labeled DNA fragmentation assays.
CONCLUSIONS: These results demonstrate that TG with its ability to elevate Cai induces proliferating prostate cancer cells to growth arrest. Such Cai dependent growth arrest is not required, however, since TG can induce the programmed death of proliferatively quiescent G0 prostatic cancer cells without requiring either growth arrest or progression through the proliferative cell cycle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365549     DOI: 10.1002/(sici)1097-0045(19971101)33:3<201::aid-pros9>3.0.co;2-l

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  14 in total

1.  Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR).

Authors:  Frank Holtrup; Andrea Bauer; Kurt Fellenberg; Ralf A Hilger; Michael Wink; Jörg D Hoheisel
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Authors:  Samuel R Denmeade; Annastasiah M Mhaka; D Marc Rosen; W Nathaniel Brennen; Susan Dalrymple; Ingrid Dach; Claus Olesen; Bora Gurel; Angelo M Demarzo; George Wilding; Michael A Carducci; Craig A Dionne; Jesper V Møller; Poul Nissen; S Brøgger Christensen; John T Isaacs
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

3.  A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Authors:  Oren Levy; W Nathaniel Brennen; Edward Han; David Marc Rosen; Juliet Musabeyezu; Helia Safaee; Sudhir Ranganath; Jessica Ngai; Martina Heinelt; Yuka Milton; Hao Wang; Sachin H Bhagchandani; Nitin Joshi; Neil Bhowmick; Samuel R Denmeade; John T Isaacs; Jeffrey M Karp
Journal:  Biomaterials       Date:  2016-03-17       Impact factor: 12.479

4.  Prostate cancer: epidemiology and screening.

Authors:  Timothy J Wilt
Journal:  Rev Urol       Date:  2003

5.  Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

Authors:  S R Denmeade; W Lou; J Lövgren; J Malm; H Lilja; J T Isaacs
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

6.  Inhibitory effects of extracellular Mg2+ on intracellular Ca2+ dynamic changes and thapsigargin-induced apoptosis in human cancer MCF7 cells.

Authors:  Manuella Pereira; Jean-Marc Millot; Stephane Sebille; Michel Manfait
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

7.  From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development.

Authors:  Søren Brøgger Christensen; Henrik Toft Simonsen; Nikolai Engedal; Poul Nissen; Jesper Vuust Møller; Samuel R Denmeade; John T Isaacs
Journal:  Prog Chem Org Nat Prod       Date:  2021

8.  Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

Authors:  W Nathaniel Brennen; D Marc Rosen; Hao Wang; John T Isaacs; Samuel R Denmeade
Journal:  J Natl Cancer Inst       Date:  2012-08-21       Impact factor: 13.506

9.  Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.

Authors:  Donald J Vander Griend; Lizamma Antony; Susan L Dalrymple; Yi Xu; S Brogger Christensen; Samuel R Denmeade; John T Isaacs
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

Review 10.  Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.

Authors:  K S Chaudhary; P D Abel; E N Lalani
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.